SER

1.1206.67%
RW

Randall W. Moreadith

Chief Development Officer

Dr. Randall W. Moreadith, M.D., Ph.D., has been Chief Development Officer of Serina Therapeutics, Inc. since March 2024 and served as its Chief Scientific Officer March 26, 2024. Dr. Moreadith had been Chief Executive Officer of Serina Therapeutics, Inc. since September 2010 and served as President. Dr. Moreadith served as Chief Development Officer and Senior Vice President of Drug Development at Nektar Therapeutics from August 11, 2008 to November 30, 2009. Dr. Moreadith had been an Executive Vice President of Cardium Therapeutics Inc. since January 2006 until August 2008. He served as the Chief Medical Officer of Tissue Repair Company from August 2006. He served as the Chief Medical Officer of Cardium Therapeutics Inc., from January 2006 to July 2008. Dr. Moreadith served as an Executive Vice President and Chief Medical Officer of Aries Ventures Inc. since January 2006. He served as the Chief Medical Officer of Renovis Inc. from August 2004 to December 2005. He served as Chief Medical Officer of InnerCool Therapies. Dr. Moreadith oversaw all clinical trials and regulatory operations and was the spokesperson for Renovis Inc.'s clinical activities. He was a Co-Founder of ThromboGenics Ltd. and served as its President and Chief Operating Officer from December 1998 to December 2003. From April 1996 to February 1997, Dr. Moreadith served as a Principal Medical Officer of Quintiles Inc. He Co-Founded the Cardiovascular Therapeutics Group. He served as a Director of Serina Therapeutics, Inc. He was a Faculty Member of University of Texas Southwestern Medical Center where he was an Established Investigator of the American Heart Association. Dr. Moreadith has published more than 50 scientific papers and chapters, is an inventor on a number of patents and has received numerous awards for his achievements. Dr. Moreadith holds a BS in Biology and Chemistry from North Carolina State University, an MD from Duke University and a Ph.D in Biochemistry from Johns Hopkins University and was a Howard Hughes Medical Institute Postdoctoral Fellow in Genetics at Harvard Medical School.

Positions